EU summons AstraZeneca to crisis management meeting… British factory registrar supply pressure
EU pressure is rising as AstraZeneca is expected to supply only about 40% of its previously promised vaccine to the European Union in the first quarter of a novel coronavirus infection (Corona 19) vaccine.
AstraZeneca’s chief executive (CEO) refuted that the EU’s order was three months behind the UK, saying that it was not intentionally delaying supply to the EU. They are pressing to supply.
–
On the 27th (local time), the German Daily Dev said that AstraZeneca’s first quarter EU supply is expected to be only 31 million servings, which is 40% of the planned 80 million batches, and the conflict between the EU and AstraZeneca is escalating. Told.
Pascal Sorio, CEO of AstraZeneca, completely refuted allegations from the EU that AstraZeneca intentionally delayed supplying vaccines to the EU and exported it to other regions in an interview with Develt.
He said, “The production of vaccine raw materials in the EU is low, so the supply is delayed, not intentionally,” he said. “The vaccine supply contract with the UK was signed three months before the EU.”
In relation to the delay in the supply of vaccines to the EU, he explained, “We said that we would do our best, but we do not have a contractual supply obligation.”
In this regard, the EU summons AstraZeneca to the crisis management meeting, demanding a convincing basis for the delay in supply, and is increasing pressure to supply supplies to other regions such as the UK.
EU Health Commissioner Stella Kyriachides said at a press conference on the day that “the quantity produced at the UK plant is part of our purchase contract.” “Two of the four factories that AstraZeneca decided to supply vaccines to the EU are in the UK. There is” he pointed out.
/yunhap news
–
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
–
:strip_exif()/i/2000614887.jpeg?resize=150%2C150&ssl=1)